<DOC>
	<DOC>NCT01712321</DOC>
	<brief_summary>The purpose of this study is to determine whether Vilazodone is effective in the treatment of symptoms of Social Anxiety Disorder among adults.</brief_summary>
	<brief_title>Study of Vilazodone to Treat Social Anxiety Disorder</brief_title>
	<detailed_description>The proposed study is a 12 week double-blind, placebo-controlled trial in which daily doses of vilazodone 20 to 40 mg/day or matching placebo will be administered on a 1:1 ratio. The study will include 30 outpatients age 18-75 with SAD, generalized subtype who return for at least one post randomization visit where efficacy evaluations are conducted.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<criteria>Diagnosis of Social Anxiety Disorder, generalized subtype LSAS total score of 70 at visits 1 and 2 Lifetime history of Bipolar disorder or Schizophrenia Current suicidal risk Current unstable medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Social Anxiety Disorder</keyword>
	<keyword>Social Anxiety</keyword>
	<keyword>Social Phobia</keyword>
	<keyword>SAD</keyword>
</DOC>